CliffBio
small molecule

FLUTICASONE PROPIONATE

FLUTICASONE PROPIONATE

Loss of exclusivity—loss of exclusivity
CompanyTaro Pharmaceutical Industries →See this company's full patent-cliff portfolio

Drug detail

Brand nameFLUTICASONE PROPIONATE
Active ingredientFLUTICASONE PROPIONATE
Strength0.005%
Dosage formOINTMENT
RouteTOPICAL
ModalitySmall molecule
FDA approvalJune 2005
Marketing statusDISCN

More from Taro Pharmaceutical Industries

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.